Sei Investments Co. Lowers Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Sei Investments Co. decreased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 296,915 shares of the specialty pharmaceutical company's stock after selling 16,825 shares during the quarter. Sei Investments Co. owned about 0.54% of Supernus Pharmaceuticals worth $10,736,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in SUPN. Smartleaf Asset Management LLC increased its holdings in shares of Supernus Pharmaceuticals by 219.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Newbridge Financial Services Group Inc. purchased a new position in Supernus Pharmaceuticals in the fourth quarter valued at about $72,000. Venturi Wealth Management LLC acquired a new stake in shares of Supernus Pharmaceuticals during the 4th quarter valued at approximately $92,000. KBC Group NV boosted its stake in shares of Supernus Pharmaceuticals by 53.1% during the 4th quarter. KBC Group NV now owns 2,679 shares of the specialty pharmaceutical company's stock worth $97,000 after acquiring an additional 929 shares in the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of Supernus Pharmaceuticals in the 4th quarter worth approximately $211,000.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on SUPN shares. StockNews.com upgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Tuesday. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th.

Remove Ads

Insider Activity

In related news, SVP Jonathan Rubin sold 927 shares of the firm's stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 700 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total transaction of $27,734.00. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,103.38. This trade represents a 6.45 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock valued at $440,263 over the last quarter. Company insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Price Performance

SUPN traded down $0.33 during trading on Thursday, hitting $32.49. The company's stock had a trading volume of 542,618 shares, compared to its average volume of 480,538. Supernus Pharmaceuticals, Inc. has a twelve month low of $25.53 and a twelve month high of $40.28. The stock has a market cap of $1.81 billion, a PE ratio of 30.36 and a beta of 0.84. The firm's 50 day moving average price is $34.68 and its 200-day moving average price is $35.03.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.